Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipients

Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210526004

Enrollment

Registered

2021-05-26

Start date

2021-06-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipients liver transplant, vaccine, COVID-19, SARS-CoV-2, safety

Interventions

Liver transplant recipients in liver transplant clinic

Diagnostic

Liver transplant recipients

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Liver transplant recipients who fulfil 1. Liver transplantation more than 3 months 2. No acute cellular rejection within 1 month

Exclusion criteria

Exclusion criteria: 1. History of SARS-CoV-2 infection 2. Pregnancy or lactation 3. Anaphylaxis to COVID-19 vaccine

Design outcomes

Primary

Measure	Time frame
Immunogenicity of vaccine 1 and 3 months after primary vaccination & 1 month after booster dose Neutralizing antibody and t-cell specific response	—

Secondary

Measure	Time frame
Safety of vaccine 1 and 3 months after primary vaccination & 1 month after booster dose Patient reported adverse events	—

Countries

Thailand

Contacts

Public ContactSupachaya Sriphoosanaphan

Faculty of Medicine, Chulalongkorn University

supachaya.sr@gmail.com022564691

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026